Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Takeda Snags Japan Rights to ImmunoGen’s ADC
Takeda Pharmaceutical has grabbed the rights to exclusively develop and commercialize US biotech ImmunoGen’s antibody-drug conjugate (ADC) mirvetuximab soravtansine-gynx (MIRV), known as Elahere overseas, for the Japanese market. Under their pact, Takeda will obtain an exclusive license in Japan to…
To read the full story
Related Article
- Takeda Files ImmunoGen-Paired ADC for Ovarian Cancer in Japan
February 2, 2026
BUSINESS
- Astellas Taps Sanofi Japan Chief Iwaya as Strategy Officer
April 28, 2026
- FRONTEO, Science Tokyo Roll Out AI Drug Discovery Hub
April 28, 2026
- Kyorin to Transfer Generics Unit to Daito-Led JV
April 28, 2026
- Guardant360 Snags Japan OK as CDx for AZ’s Camizestrant
April 28, 2026
- Meiji Begins Japan PI/II Trial of Rezurock in Pediatric GVHD
April 28, 2026
AAV (adeno-associated virus) gene therapies are moving beyond rare diseases into more prevalent conditions, with neovascular, or wet, age-related macular…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…